<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chordoma and chondrosarcoma of the skull base</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chordoma and chondrosarcoma of the skull base</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chordoma and chondrosarcoma of the skull base</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carl Snyderman, MD, MBA</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Y Wen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marvin P Fried, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 13, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The anatomic junction of the neural and facial viscerocranium is termed the skull base  (<a class="graphic graphic_figure graphicRef60335 graphicRef65811" href="/d/graphic/60335.html" rel="external">figure 1A-B</a>). This area is critically important because it supports the brain and allows all the neurovascular structures to either enter or exit the skull.</p><p>Neoplasms may originate within the skull base or involve it by growth from either the dura or extracranial structures. Skull base tumors include a number of different histologic cell types.</p><p>Chordoma and chondrosarcoma arising in the skull base will be reviewed here. Topics discussed elsewhere include:</p><p class="bulletIndent1"><span class="glyph">●</span>Chordomas arising in the sacrum or elsewhere along the spinal cord (see  <a class="medical medical_review" href="/d/html/5227.html" rel="external">"Spinal cord tumors"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chondrosarcomas at sites other than the skull base (see  <a class="medical medical_review" href="/d/html/7724.html" rel="external">"Chondrosarcoma"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other histologic tumor types involving the skull base (see appropriate topic reviews).</p><p></p><p class="headingAnchor" id="H1025362761"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H287166283"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>The clinical presentation of a skull base tumor depends in part upon the site of origin of the tumor and its direction of growth.</p><p>Most patients with a skull base tumor complain of headache and intermittent diplopia. Gradually, headache worsens with upper clivus tumors and neck pain develops with lower clivus tumors. Invasion of the cavernous sinus can produce diplopia and facial numbness. Lower clivus tumors initially compress the lower cranial nerves; brainstem compression may follow. The diagnosis of a clival chordoma is often delayed because symptoms are vague.</p><p>The clinical features of chordoma and chondrosarcoma are similar [<a href="#rid1">1,2</a>]. In one series of 48 patients with chordoma and 49 with low-grade chondrosarcoma, headache and diplopia from abducens nerve palsy was common in both groups [<a href="#rid1">1</a>]. Normal neurologic examinations were more common in patients with chordoma, while visual loss, facial numbness, and multiple cranial neuropathies were more common in patients with chondrosarcoma. These differences probably reflect the tendency of chordomas to originate from the clivus and chondrosarcomas from the petroclival fissure (junction of clivus and temporal bone).</p><p class="headingAnchor" id="H4"><span class="h2">Imaging studies</span><span class="headingEndMark"> — </span>Magnetic resonance imaging (MRI) is the best technique to assess the soft tissue extent of tumor and visualize its dural extension [<a href="#rid3">3</a>]. Chordomas and chondrosarcomas are typically heterogeneously bright on T2-weighted images, which can aid with diagnosis. Most tumors are associated with heterogeneous contrast enhancement. CT scan is more effective for demonstrating bone lesions  (<a class="graphic graphic_diagnosticimage graphicRef79863" href="/d/graphic/79863.html" rel="external">image 1</a>). Calcification is not uncommon with chondrosarcoma. The characteristic ring-forming calcifications seen on computed tomography (CT) scans can be correlated with the histologic pattern of calcification [<a href="#rid4">4</a>]. CT MRI image fusion may provide additional anatomic information regarding the tumor and surrounding tissues [<a href="#rid5">5</a>].</p><p>Chondrosarcomas typically originate laterally at the petroclival junction, but there are no pathognomonic imaging findings that distinguish chordoma from chondrosarcoma. Although imaging studies may result in a working diagnosis, biopsy and histologic studies are necessary to confirm the diagnosis. Both chordomas and chondrosarcomas can be staged according to the tumor, node, metastasis (TNM) system for primary malignant tumors of bone  (<a class="graphic graphic_table graphicRef110737" href="/d/graphic/110737.html" rel="external">table 1</a>), but this has limited prognostic value in the skull base region. </p><p>Chordomas appear heterogeneous on 18-F fluorodeoxyglucose positron emission tomography (FDG-PET) [<a href="#rid6">6</a>]. FDG-PET may be useful as a modality for staging, evaluation of treatment response, and assessing for recurrent or metastatic disease in combination with CT or MRI.</p><p>Ecchordosis physaliphora (EP), a benign notochordal remnant, is described in approximately 2 percent of autopsy specimens and can mimic clival chordoma radiographically [<a href="#rid7">7</a>]. EP usually appears as a small (&lt;2 cm), well-circumscribed focus of T2 hyperintensity on the dorsal surface of the clivus in the midline. Unlike chordoma, EP is nonenhancing and rarely shows evidence of clival erosion on CT. A characteristic bony stalk or pedicle at the base of the mass is present in approximately two-thirds of cases and is a useful diagnostic clue. EP is a radiologic diagnosis that can be observed in most cases; lesions with atypical imaging findings should be followed over time to ensure stability.</p><p class="headingAnchor" id="H5"><span class="h1">PATHOLOGY</span></p><p class="headingAnchor" id="H6"><span class="h2">Chordomas</span><span class="headingEndMark"> — </span>Chordomas are rare, slow-growing, locally aggressive neoplasms of bone that arise from embryonic remnants of the notochord. These tumors typically occur in the axial skeleton and are most common in the sphenooccipital region of the skull base and in the sacral regions [<a href="#rid8">8-13</a>]. In adults, approximately one-third of chordomas involve the sacrococcygeal region, one-third occur at the base of the skull, and one-third are found elsewhere in the vertebral column [<a href="#rid14">14</a>]. Craniocervical chordomas most often involve the dorsum sella, clivus, and nasopharynx. (See  <a class="medical medical_review" href="/d/html/5227.html" rel="external">"Spinal cord tumors", section on 'Chordomas'</a>.)</p><p>Chordomas are divided into three subgroups [<a href="#rid14">14,15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Conventional chordomas are the most common. They are characterized by the absence of cartilaginous or other mesenchymal components. Chondroid chordoma is a subtype of conventional chordoma containing matrix that mimics hyaline cartilage.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dedifferentiated chordomas are biphasic tumors composed of a sarcomatous component, which may be a malignant fibrous histiocytoma, fibrosarcoma, osteosarcoma, or chondrosarcoma, interspersed with areas of conventional chordoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poorly differentiated chordomas are epithelioid and solid tumors with focal rhabdoid morphology. They are characterized by homozygous SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily b, member 1 (<em>SMARCB1</em>) deletions, which can be detected immunohistochemically by loss of SMARCB1 (INI1) expression. Most of these tumors occur in children and are located in the skull base.</p><p></p><p>On gross examination, chordomas are gelatinous pink or gray masses with solid and cystic areas. Microscopically, they are composed of lobules that contain epithelioid cells arranged in cords or clusters and separated by fibrous strands in a mucinous matrix. The tumor cells have vesicular nuclei and abundant vacuolated, soap bubble-like cytoplasm (physaliphorous cells) that contains glycogen (periodic acid-Schiff [PAS] positive) or mucin  (<a class="graphic graphic_picture graphicRef76084" href="/d/graphic/76084.html" rel="external">picture 1</a>). Nuclear pleomorphism and mitoses are uncommon. Ultrastructurally, chordomas exhibit epithelial features with prominent desmosomes.</p><p>Tumor cells in almost all chordomas are diffusely and strongly positive for cytokeratin. Staining for epithelial membrane antigen (EMA) is present in more than 80 percent of cases, although it is typically more focal and less strongly positive than other antigen stains [<a href="#rid16">16-19</a>]. Expression of brachyury, a key transcription factor in notochord development, appears to be a sensitive and specific biomarker of chordoma, and immunohistochemical staining for brachyury is routinely performed to help distinguish chordoma from cartilaginous tumors [<a href="#rid20">20</a>]. </p><p>Other immunostains are variable depending upon the type of chordoma. In one study, all 16 classic chordomas stained for keratin, while only 32 percent of 25 chondroid chordomas did [<a href="#rid16">16</a>]. In the same study, 44 percent of the classic and 85 percent of the chondroid chordomas were positive for S-100 protein [<a href="#rid16">16</a>]. </p><p class="headingAnchor" id="H7"><span class="h2">Chondrosarcomas</span><span class="headingEndMark"> — </span>Chondrosarcomas are rare malignant cartilaginous tumors that make up 11 percent of primary malignant bone neoplasms and account for approximately 6 percent of all skull base tumors [<a href="#rid4">4,21,22</a>]. Most skull base chondrosarcomas arise in the middle fossa, followed by the posterior or anterior fossae.</p><p>Grossly, chondrosarcomas are smooth, lobulated, hard tumors, and often are more than 2 cm in diameter  (<a class="graphic graphic_picture graphicRef60109" href="/d/graphic/60109.html" rel="external">picture 2</a>). Microscopically, they are lobulated and, depending upon their degree of differentiation, show increased cellularity, with hyperchromatic and pleomorphic tumor cells, prominent nucleoli, and binucleated or multinucleated chondrocytes.</p><p>Microscopic grading has prognostic value in chondrosarcomas [<a href="#rid14">14,23</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Well-differentiated (grade 1) chondrosarcomas are moderately cellular with an abundant hyaline cartilage matrix. They consist of chondrocytes with small, round nuclei and occasional binucleated cells. Mitoses are absent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderately differentiated (grade 2) chondrosarcomas have more cellularity and less matrix than grade 1 tumors, and mitoses are widely scattered in the tumor. The nuclei of chondrocytes are enlarged, vesicular or hyperchromatic, and often show more than one cell in a lacuna.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poorly differentiated (grade 3) tumors display even more cellularity and nuclear pleomorphism than grade 2 tumors. Cords or clumps of chondrocytes have irregular, vesicular or spindle-shaped nuclei, less matrix, and easily found mitoses.</p><p></p><p>The majority of skull base chondrosarcomas are chondrosarcoma grade 1 (CS1) and, less commonly, grade 2 tumors  (<a class="graphic graphic_picture graphicRef70909" href="/d/graphic/70909.html" rel="external">picture 3</a>) [<a href="#rid24">24</a>]. Osteoid metaplasia may be present within a chondrosarcoma and is distinguished from the chondroblastic variant of osteosarcoma by the absence of osteoid that is lined by cytologically atypical osteoblasts.</p><p>Pathogenic variants in the isocitrate dehydrogenase type 1 (<em>IDH1</em>) or isocitrate dehydrogenase type 2 (<em>IDH2</em>) genes are present in approximately half of chondrosarcomas. Skull base chondrosarcomas occur in rare patients with Ollier disease and Maffucci syndrome, which are caused by somatic mosaic mutations in <em>IDH1</em> and <em>IDH2 </em>[<a href="#rid25">25,26</a>]. (See  <a class="medical medical_review" href="/d/html/7724.html" rel="external">"Chondrosarcoma", section on 'Molecular pathogenesis'</a>.)</p><p>Other rare types of chondrosarcoma that may present at the skull base include high-grade mesenchymal chondrosarcoma and the so-called extraskeletal myxoid chondrosarcoma. (See  <a class="medical medical_review" href="/d/html/7724.html" rel="external">"Chondrosarcoma", section on 'Classification, histology, and clinical features'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Distinguishing chordoma from chondrosarcoma can be difficult histologically but is important because of the significantly better prognosis associated with chondrosarcomas [<a href="#rid24">24</a>]. The histologic differential diagnosis of chordoma and chondrosarcoma also includes mucinous adenocarcinoma and myxopapillary ependymoma  (<a class="graphic graphic_table graphicRef53974" href="/d/graphic/53974.html" rel="external">table 2</a>).</p><p>Immunohistochemistry is an important tool in establishing the diagnosis:</p><p class="bulletIndent1"><span class="glyph">●</span>Chondrosarcomas do not express cytokeratin, while S-100 protein expression is present in both chondrosarcomas and chordomas [<a href="#rid24">24,27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumor cells in chondrosarcoma and myxopapillary ependymoma are negative for cytokeratin and EMA, unlike chordomas [<a href="#rid17">17-19</a>]. In addition, they do not have desmosomes on ultrastructural examination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Only myxopapillary ependymoma is positive for glial fibrillary acidic protein (GFAP), while chordomas and chondrosarcomas are negative for this marker. In one series, immunoreactivity was present for vimentin and GFAP in all cases and for S-100 protein in 50 percent of myxopapillary ependymomas [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The differentiation of adenocarcinoma from chordoma may be difficult because both neoplasms are cytokeratin and EMA positive. Although positivity for vimentin and S-100 protein supports the diagnosis of chordoma over adenocarcinoma, this finding should be interpreted with caution, as rare adenocarcinomas may be positive for S-100 protein.</p><p></p><p class="headingAnchor" id="H9"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>There are no randomized clinical trials and no large prospective series that define the optimal treatment for either chordomas or chondrosarcomas.</p><p>Literature reviews of small retrospective series and expert consensus support a combined-modality approach using maximal surgical resection and radiation therapy (RT) [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>Surgery is performed both to obtain tissue for diagnosis and to reduce the tumor burden [<a href="#rid29">29</a>]. Complete resection is desirable for both chordomas and chondrosarcomas of the skull base. However, a complete resection is often not feasible because of anatomic constraints to surgical access and proximity to critical normal structures. Both open (transcranial and transfacial) and endoscopic endonasal surgical approaches are successfully used for these tumors. There is evidence from observational studies that gross total resection of chordomas is better facilitated with a midline endoscopic endonasal approach [<a href="#rid30">30-32</a>].</p><p>Although these tumors are slow growing, they are locally invasive tumors and there is a high incidence of local recurrence that can result in death due to uncontrolled local disease. For patients with chondrosarcoma, metastases occur in approximately 10 percent of cases. For patients with chordoma, dedifferentiation or sarcomatous transformation occurs in 2 to 8 percent of chordomas [<a href="#rid33">33,34</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Radiation therapy</span><span class="headingEndMark"> — </span>Tumors involving the skull base are difficult to manage as a result of their proximity to critical neural structures. Maximal surgical resection is the mainstay of therapy, but complete resections are difficult to achieve, and recurrent tumors are associated with a poorer prognosis.</p><p>Adjuvant RT is therefore suggested for most patients, although it has been difficult to administer adequately high doses of radiation with older techniques [<a href="#rid28">28,35</a>].</p><p>High-dose focused radiation delivery techniques with particles (primarily protons) or photons (stereotactic radiosurgery [SRS], stereotactic radiation therapy [SRT], and intensity-modulated radiation therapy [IMRT]) allow for higher doses of RT to be delivered to the tumor while sparing surrounding structures. The most extensive data come from proton beam therapy, but there are no randomized trials comparing these different contemporary techniques, and the advantages of proton beam therapy are primarily theoretical and anecdotal.</p><p>Conventional two- or three-dimensional RT techniques using photons have a significant risk of damaging the brainstem and cranial nerves, and the lower doses historically used with these techniques have been associated with a high rate of local recurrence and treatment failure. The limitations of photon therapy in the treatment of chordomas are illustrated by a series of 48 patients (20 with skull base lesions), 44 of whom had macroscopic disease following surgery [<a href="#rid36">36</a>]. The local control rate with conventional photon radiation was only 27 percent, although 85 percent of patients achieved useful and prolonged palliation of pain. The median survival was 62 months.</p><p class="headingAnchor" id="H12"><span class="h3">Charged particle RT</span><span class="headingEndMark"> — </span>Charged particle irradiation offers several theoretical advantages over conventional photon RT to minimize incidental irradiation to adjuvant normal structures. (See  <a class="medical medical_review" href="/d/html/89528.html" rel="external">"Radiation therapy techniques in cancer treatment", section on 'Particle therapy'</a>.)</p><p>Proton beam RT is the most widely used charged ion technique. This approach appears to be more effective than earlier use of conventional photon RT with lower doses of radiation:</p><p class="bulletIndent1"><span class="glyph">●</span>Chordomas – Proton therapy for chordoma typically involves a total radiation dose of 70 Gy equivalents or higher. In systematic reviews of retrospective studies, local control is achieved in approximately 75 percent of patients with three to five years of follow-up [<a href="#rid37">37,38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chondrosarcomas – In patients with chondrosarcoma, the largest series comprised 200 patients treated at a single institution [<a href="#rid24">24</a>]. The median total dose of radiation in that series was 72 Gy equivalents. The 10-year local control and survival rates were 98 and 99 percent, respectively. A subsequent review of the literature included that series plus 54 patients with chondrosarcoma identified in three other studies; the results in those series were similar [<a href="#rid39">39</a>].</p><p></p><p>Other charged particles, especially carbon ions, have been used in addition to protons in patients with skull base chordoma and chondrosarcoma [<a href="#rid37">37,38,40-44</a>]. Although these approaches appear to have similar efficacy to proton therapy, there are no comparative studies and these techniques are not widely available.</p><p class="headingAnchor" id="H13"><span class="h3">Photon techniques</span><span class="headingEndMark"> — </span>Several other techniques have been used to deliver higher doses of photon radiation to central nervous system targets, while minimizing incidental exposure to normal critical structures. There are no randomized trials that compare SRS, SRT, or IMRT with proton beam or older photon techniques.</p><p class="bulletIndent1"><span class="glyph">●</span>Experience with SRS has been reported in several retrospective series [<a href="#rid45">45,46</a>]. A review of the literature identified five published series of SRS for chordoma [<a href="#rid46">46</a>]. In total, 168 patients were treated with a median follow-up of 34 to 60 months. Progression-free survival at five years ranged from 21 to 72 percent. SRS is limited to tumors with a relatively small tumor volume.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SRT can be used for larger lesions than SRS. In one series of 37 chordoma patients treated with SRT, the five-year survival rate was 82 percent, although the mean follow-up was only 27 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Favorable local control rates and survival have also been reported in small studies using IMRT for skull base chordomas and chondrosarcomas [<a href="#rid47">47</a>].</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Advanced disease</span></p><p class="headingAnchor" id="H15"><span class="h3">Chondrosarcoma</span><span class="headingEndMark"> — </span>Historically, chondrosarcomas have been considered resistant to chemotherapy. Although the majority of patients with recurrent or metastatic sarcoma do not respond to the usual chemotherapy regimens for advanced sarcoma, there have been isolated reports of successful treatment with <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a> plus <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> or single-agent <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>.</p><p>Chemotherapy for advanced chondrosarcomas is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7724.html" rel="external">"Chondrosarcoma", section on 'Systemic treatment'</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Chordoma</span><span class="headingEndMark"> — </span>A variety of molecular targets may be relevant therapeutically in chordoma, including platelet-derived growth factor receptor (PDGFR), epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), mammalian target of rapamycin (mTOR), and INI1 [<a href="#rid48">48-50</a>]. Identification of specific tumor markers in chordomas may provide prognostic information that can be used to guide decision-making and the selection of additional therapy. In some cases, participation in clinical trials investigating immunotherapy and other novel approaches may be considered for the treatment of residual, recurrent, or metastatic disease [<a href="#rid51">51-53</a>].</p><p>Studies reporting the use of molecularly targeted agents such as <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> in patients with advanced chordoma are discussed separately. (See  <a class="medical medical_review" href="/d/html/5227.html" rel="external">"Spinal cord tumors", section on 'Chordomas'</a>.)</p><p class="headingAnchor" id="H1443193377"><span class="h2">Familial chordoma</span><span class="headingEndMark"> — </span>Rare families with susceptibility to chordoma have been described, some in association with germline duplication of the T-box transcription factor T (<em>TBXT</em>) gene [<a href="#rid54">54</a>]. Factors that may indicate a higher likelihood of a genetic predisposition include young age at diagnosis, skull base location, and multiple primary chordomas [<a href="#rid55">55</a>]. Patients with a family history of chordoma and those presenting at an early age (eg, &lt;30 years) should undergo complete imaging of the neuroaxis to evaluate for multiple tumors and be referred for genetic counseling and testing. </p><p>Chordoma in early childhood can be seen rarely in patients with tuberous sclerosis [<a href="#rid56">56</a>], which is caused by germline gain-of-function mutations in the tuberous sclerosis complex 1 (<em>TSC1</em>) or <em>TSC2</em> gene. (See  <a class="medical medical_review" href="/d/html/6175.html" rel="external">"Tuberous sclerosis complex: Clinical features"</a>.)</p><p class="headingAnchor" id="H2609387931"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/134680.html" rel="external">"Society guideline links: Bone sarcomas"</a>.)</p><p class="headingAnchor" id="H113088467"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83152.html" rel="external">"Patient education: Chondrosarcoma (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Both chordomas and chondrosarcomas are rare tumors that can arise in the skull base. Because of their anatomic location and proximity to critical structures, complete resection is difficult and local recurrences are frequent. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chordomas are rare, slow-growing, locally aggressive neoplasms of bone that arise from embryonic remnants of the notochord. Chondrosarcomas are rare malignant cartilaginous tumors composed of chondrocytes within an abundant hyaline cartilage matrix. (See <a class="local">'Pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a primary tumor of the skull base, initial surgical resection can provide a tissue diagnosis. A complete or near complete resection may be associated with a prolonged disease-free period and may enhance the effectiveness of subsequent radiation therapy (RT). (See <a class="local">'Surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a chordoma, we suggest adjuvant RT following surgery rather than observation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). This approach appears to be associated with a longer disease-free period, and salvage therapy has generally not been successful in patients with chordomas. Many patients with recurrent disease are candidates for additional surgery. (See <a class="local">'Radiation therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with a chondrosarcoma, we suggest adjuvant RT following maximal surgical resection (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients with a low-grade tumor who have undergone a gross total resection, deferring RT is an alternative, and patients who recur should be retreated aggressively with surgery and/or RT. (See <a class="local">'Radiation therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When RT is indicated, achieving an adequate tumor dose while minimizing damage to critical neurologic structures is critical. Radiation should be delivered using high-dose focused proton or photon radiation delivery technology. Options include proton beam radiation and contemporary photon-based techniques, such as stereotactic radiosurgery (SRS), stereotactic radiation therapy (SRT), or intensity-modulated radiation therapy (IMRT). Of these, we suggest proton beam RT when this modality is available (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="headingAnchor" id="H3254995138"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Derrick Lin, MD, who contributed to an earlier version of this topic review. </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Volpe NJ, Liebsch NJ, Munzenrider JE, Lessell S. Neuro-ophthalmologic findings in chordoma and chondrosarcoma of the skull base. Am J Ophthalmol 1993; 115:97.</a></li><li><a class="nounderline abstract_t">Korten AG, ter Berg HJ, Spincemaille GH, et al. Intracranial chondrosarcoma: review of the literature and report of 15 cases. J Neurol Neurosurg Psychiatry 1998; 65:88.</a></li><li><a class="nounderline abstract_t">Meyers SP, Hirsch WL Jr, Curtin HD, et al. Chondrosarcomas of the skull base: MR imaging features. Radiology 1992; 184:103.</a></li><li><a class="nounderline abstract_t">Rassekh CH, Nuss DW, Kapadia SB, et al. Chondrosarcoma of the nasal septum: skull base imaging and clinicopathologic correlation. Otolaryngol Head Neck Surg 1996; 115:29.</a></li><li><a class="nounderline abstract_t">Leong JL, Batra PS, Citardi MJ. CT-MR image fusion for the management of skull base lesions. Otolaryngol Head Neck Surg 2006; 134:868.</a></li><li><a class="nounderline abstract_t">Olson JT, Wenger DE, Rose PS, et al. Chordoma: 18F-FDG PET/CT and MRI imaging features. Skeletal Radiol 2021; 50:1657.</a></li><li><a class="nounderline abstract_t">Park HH, Lee KS, Ahn SJ, et al. Ecchordosis physaliphora: typical and atypical radiologic features. Neurosurg Rev 2017; 40:87.</a></li><li><a class="nounderline abstract_t">Heffelfinger MJ, Dahlin DC, MacCarty CS, Beabout JW. Chordomas and cartilaginous tumors at the skull base. Cancer 1973; 32:410.</a></li><li class="breakAll">Chordoma. In: Bone Tumors: Diagnosis, Treatment and Prognosis, 2nd ed, WB Saunders, Philadelphia 1991. p.599.</li><li><a class="nounderline abstract_t">Perzin KH, Pushparaj N. Nonepithelial tumors of the nasal cavity, paranasal sinuses, and nasopharynx. A clinicopathologic study. XIV: Chordomas. Cancer 1986; 57:784.</a></li><li><a class="nounderline abstract_t">Harbour JW, Lawton MT, Criscuolo GR, et al. Clivus chordoma: a report of 12 recent cases and review of the literature. Skull Base Surg 1991; 1:200.</a></li><li><a class="nounderline abstract_t">Volpe R, Mazabraud A. A clinicopathologic review of 25 cases of chordoma (a pleomorphic and metastasizing neoplasm). Am J Surg Pathol 1983; 7:161.</a></li><li><a class="nounderline abstract_t">Rich TA, Schiller A, Suit HD, Mankin HJ. Clinical and pathologic review of 48 cases of chordoma. Cancer 1985; 56:182.</a></li><li class="breakAll">Soft tissue and bone tumours. In: WHO Classification of Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), IARC Press, 2020.</li><li class="breakAll">Central Nervous System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, 2021.</li><li><a class="nounderline abstract_t">Mitchell A, Scheithauer BW, Unni KK, et al. Chordoma and chondroid neoplasms of the spheno-occiput. An immunohistochemical study of 41 cases with prognostic and nosologic implications. Cancer 1993; 72:2943.</a></li><li><a class="nounderline abstract_t">Abenoza P, Sibley RK. Chordoma: an immunohistologic study. Hum Pathol 1986; 17:744.</a></li><li><a class="nounderline abstract_t">Coffin CM, Swanson PE, Wick MR, Dehner LP. An immunohistochemical comparison of chordoma with renal cell carcinoma, colorectal adenocarcinoma, and myxopapillary ependymoma: a potential diagnostic dilemma in the diminutive biopsy. Mod Pathol 1993; 6:531.</a></li><li><a class="nounderline abstract_t">Meis JM, Giraldo AA. Chordoma. An immunohistochemical study of 20 cases. Arch Pathol Lab Med 1988; 112:553.</a></li><li><a class="nounderline abstract_t">Vujovic S, Henderson S, Presneau N, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 2006; 209:157.</a></li><li><a class="nounderline abstract_t">Adegbite AB, McQueen JD, Paine KW, Rozdilsky B. Primary intracranial chondrosarcoma: a report of two cases. Neurosurgery 1985; 17:490.</a></li><li><a class="nounderline abstract_t">Sen CN, Sekhar LN, Schramm VL, Janecka IP. Chordoma and chondrosarcoma of the cranial base: an 8-year experience. Neurosurgery 1989; 25:931.</a></li><li class="breakAll">Hogendoorn PCW, Bovee JM, Nielsen GP. Chondrosarcoma (grades I-III), including primary and secondary variants and periosteal chondrosarcoma. In: World Health Organization classification of tumours of soft tissue and bone, 4th ed, Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (Eds), IARC, Lyon 2013. Vol 5, p.264.</li><li><a class="nounderline abstract_t">Rosenberg AE, Nielsen GP, Keel SB, et al. Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma. Am J Surg Pathol 1999; 23:1370.</a></li><li><a class="nounderline abstract_t">Ding C, Chen W, Liu F, et al. Skull Base Chondrosarcoma Caused by Ollier Disease: A Case Report and Literature Review. World Neurosurg 2019; 127:103.</a></li><li><a class="nounderline abstract_t">Abdelmalek M, Stanko C. Recurrent chondrosarcoma of the right skull base in a patient with Maffucci syndrome. Am J Clin Dermatol 2008; 9:61.</a></li><li><a class="nounderline abstract_t">Gherardi G, Marveggio C, Cola C, Redaelli G. Decisive role of immunocytochemistry in aspiration cytology of chordoma of the clivus: a case report with review of the literature. J Laryngol Otol 1994; 108:426.</a></li><li><a class="nounderline abstract_t">Stacchiotti S, Sommer J, Chordoma Global Consensus Group. Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol 2015; 16:e71.</a></li><li><a class="nounderline abstract_t">Fernandez-Miranda JC, Gardner PA, Snyderman CH, et al. Clival chordomas: A pathological, surgical, and radiotherapeutic review. Head Neck 2014; 36:892.</a></li><li><a class="nounderline abstract_t">Koutourousiou M, Snyderman CH, Fernandez-Miranda J, Gardner PA. Skull base chordomas. Otolaryngol Clin North Am 2011; 44:1155.</a></li><li><a class="nounderline abstract_t">Koutourousiou M, Gardner PA, Tormenti MJ, et al. Endoscopic endonasal approach for resection of cranial base chordomas: outcomes and learning curve. Neurosurgery 2012; 71:614.</a></li><li><a class="nounderline abstract_t">Cannizzaro D, Tropeano MP, Milani D, et al. Microsurgical versus endoscopic trans-sphenoidal approaches for clivus chordoma: a pooled and meta-analysis. Neurosurg Rev 2021; 44:1217.</a></li><li><a class="nounderline abstract_t">Meis JM, Raymond AK, Evans HL, et al. "Dedifferentiated" chordoma. A clinicopathologic and immunohistochemical study of three cases. Am J Surg Pathol 1987; 11:516.</a></li><li><a class="nounderline abstract_t">Hruban RH, Traganos F, Reuter VE, Huvos AG. Chordomas with malignant spindle cell components. A DNA flow cytometric and immunohistochemical study with histogenetic implications. Am J Pathol 1990; 137:435.</a></li><li><a class="nounderline abstract_t">De Amorim Bernstein K, DeLaney T. Chordomas and chondrosarcomas-The role of radiation therapy. J Surg Oncol 2016; 114:564.</a></li><li><a class="nounderline abstract_t">Catton C, O'Sullivan B, Bell R, et al. Chordoma: long-term follow-up after radical photon irradiation. Radiother Oncol 1996; 41:67.</a></li><li><a class="nounderline abstract_t">Alahmari M, Temel Y. Skull base chordoma treated with proton therapy: A systematic review. Surg Neurol Int 2019; 10:96.</a></li><li><a class="nounderline abstract_t">Zhou J, Yang B, Wang X, Jing Z. Comparison of the Effectiveness of Radiotherapy with Photons and Particles for Chordoma After Surgery: A Meta-Analysis. World Neurosurg 2018; 117:46.</a></li><li><a class="nounderline abstract_t">Amichetti M, Amelio D, Cianchetti M, et al. A systematic review of proton therapy in the treatment of chondrosarcoma of the skull base. Neurosurg Rev 2010; 33:155.</a></li><li><a class="nounderline abstract_t">Mizoe JE, Hasegawa A, Takagi R, et al. Carbon ion radiotherapy for skull base chordoma. Skull Base 2009; 19:219.</a></li><li><a class="nounderline abstract_t">Schulz-Ertner D, Karger CP, Feuerhake A, et al. Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int J Radiat Oncol Biol Phys 2007; 68:449.</a></li><li><a class="nounderline abstract_t">Uhl M, Mattke M, Welzel T, et al. High control rate in patients with chondrosarcoma of the skull base after carbon ion therapy: first report of long-term results. Cancer 2014; 120:1579.</a></li><li><a class="nounderline abstract_t">Uhl M, Mattke M, Welzel T, et al. Highly effective treatment of skull base chordoma with carbon ion irradiation using a raster scan technique in 155 patients: first long-term results. Cancer 2014; 120:3410.</a></li><li><a class="nounderline abstract_t">Koto M, Ikawa H, Kaneko T, et al. Long-term outcomes of skull base chordoma treated with high-dose carbon-ion radiotherapy. Head Neck 2020; 42:2607.</a></li><li><a class="nounderline abstract_t">Kano H, Sheehan J, Sneed PK, et al. Skull base chondrosarcoma radiosurgery: report of the North American Gamma Knife Consortium. J Neurosurg 2015; 123:1268.</a></li><li><a class="nounderline abstract_t">Kano H, Niranjan A, Lunsford LD. Radiosurgery for Chordoma and Chondrosarcoma. Prog Neurol Surg 2019; 34:207.</a></li><li><a class="nounderline abstract_t">Sahgal A, Chan MW, Atenafu EG, et al. Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and chondrosarcoma: preliminary outcomes. Neuro Oncol 2015; 17:889.</a></li><li><a class="nounderline abstract_t">Yamaguchi T, Imada H, Iida S, Szuhai K. Notochordal Tumors: An Update on Molecular Pathology with Therapeutic Implications. Surg Pathol Clin 2017; 10:637.</a></li><li><a class="nounderline abstract_t">Lebellec L, Chauffert B, Blay JY, et al. Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF). Eur J Cancer 2017; 79:119.</a></li><li><a class="nounderline abstract_t">Colia V, Stacchiotti S. Medical treatment of advanced chordomas. Eur J Cancer 2017; 83:220.</a></li><li><a class="nounderline abstract_t">Gill CM, Fowkes M, Shrivastava RK. Emerging Therapeutic Targets in Chordomas: A Review of the Literature in the Genomic Era. Neurosurgery 2020; 86:E118.</a></li><li><a class="nounderline abstract_t">Frezza AM, Botta L, Trama A, et al. Chordoma: update on disease, epidemiology, biology and medical therapies. Curr Opin Oncol 2019; 31:114.</a></li><li><a class="nounderline abstract_t">Zenonos GA, Fernandez-Miranda JC, Mukherjee D, et al. Prospective validation of a molecular prognostication panel for clival chordoma. J Neurosurg 2018; :1.</a></li><li><a class="nounderline abstract_t">Yang XR, Ng D, Alcorta DA, et al. T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat Genet 2009; 41:1176.</a></li><li><a class="nounderline abstract_t">Parry DM, McMaster ML, Liebsch NJ, et al. Clinical findings in families with chordoma with and without T gene duplications and in patients with sporadic chordoma reported to the Surveillance, Epidemiology, and End Results program. J Neurosurg 2020; 134:1399.</a></li><li><a class="nounderline abstract_t">McMaster ML, Goldstein AM, Parry DM. Clinical features distinguish childhood chordoma associated with tuberous sclerosis complex (TSC) from chordoma in the general paediatric population. J Med Genet 2011; 48:444.</a></li></ol></div><div id="topicVersionRevision">Topic 5179 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8420385" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Neuro-ophthalmologic findings in chordoma and chondrosarcoma of the skull base.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9667567" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Intracranial chondrosarcoma: review of the literature and report of 15 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1609064" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Chondrosarcomas of the skull base: MR imaging features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8758626" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Chondrosarcoma of the nasal septum: skull base imaging and clinicopathologic correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16647550" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : CT-MR image fusion for the management of skull base lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33521875" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Chordoma: 18F-FDG PET/CT and MRI imaging features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27206421" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Ecchordosis physaliphora: typical and atypical radiologic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4722921" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chordomas and cartilaginous tumors at the skull base.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4722921" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Chordomas and cartilaginous tumors at the skull base.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2417683" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Nonepithelial tumors of the nasal cavity, paranasal sinuses, and nasopharynx. A clinicopathologic study. XIV: Chordomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17170837" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clivus chordoma: a report of 12 recent cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6859391" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A clinicopathologic review of 25 cases of chordoma (a pleomorphic and metastasizing neoplasm).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2408725" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical and pathologic review of 48 cases of chordoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2408725" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical and pathologic review of 48 cases of chordoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2408725" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical and pathologic review of 48 cases of chordoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7693324" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Chordoma and chondroid neoplasms of the spheno-occiput. An immunohistochemical study of 41 cases with prognostic and nosologic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2424820" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Chordoma: an immunohistologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7504258" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : An immunohistochemical comparison of chordoma with renal cell carcinoma, colorectal adenocarcinoma, and myxopapillary ependymoma: a potential diagnostic dilemma in the diminutive biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2451900" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Chordoma. An immunohistochemical study of 20 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16538613" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4047363" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Primary intracranial chondrosarcoma: a report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2601825" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Chordoma and chondrosarcoma of the cranial base: an 8-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2601825" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Chordoma and chondrosarcoma of the cranial base: an 8-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10555005" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30872199" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Skull Base Chondrosarcoma Caused by Ollier Disease: A Case Report and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18092846" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Recurrent chondrosarcoma of the right skull base in a patient with Maffucci syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8035126" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Decisive role of immunocytochemistry in aspiration cytology of chordoma of the clivus: a case report with review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25638683" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Building a global consensus approach to chordoma: a position paper from the medical and patient community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23804541" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clival chordomas: A pathological, surgical, and radiotherapeutic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21978899" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Skull base chordomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22592328" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Endoscopic endonasal approach for resection of cranial base chordomas: outcomes and learning curve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32472379" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Microsurgical versus endoscopic trans-sphenoidal approaches for clivus chordoma: a pooled and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2440324" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : "Dedifferentiated" chordoma. A clinicopathologic and immunohistochemical study of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1696786" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Chordomas with malignant spindle cell components. A DNA flow cytometric and immunohistochemical study with histogenetic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27760458" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Chordomas and chondrosarcomas-The role of radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8961370" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Chordoma: long-term follow-up after radical photon irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31528434" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Skull base chordoma treated with proton therapy: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29879512" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparison of the Effectiveness of Radiotherapy with Photons and Particles for Chordoma After Surgery: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19921291" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A systematic review of proton therapy in the treatment of chondrosarcoma of the skull base.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19881902" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Carbon ion radiotherapy for skull base chordoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17363188" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24500784" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : High control rate in patients with chondrosarcoma of the skull base after carbon ion therapy: first report of long-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24948519" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Highly effective treatment of skull base chordoma with carbon ion irradiation using a raster scan technique in 155 patients: first long-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32472716" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Long-term outcomes of skull base chordoma treated with high-dose carbon-ion radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26115468" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Skull base chondrosarcoma radiosurgery: report of the North American Gamma Knife Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31096236" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Radiosurgery for Chordoma and Chondrosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25543126" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and chondrosarcoma: preliminary outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28797506" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Notochordal Tumors: An Update on Molecular Pathology with Therapeutic Implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28478340" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28750274" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Medical treatment of advanced chordomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504814" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Emerging Therapeutic Targets in Chordomas: A Review of the Literature in the Genomic Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30585858" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Chordoma: update on disease, epidemiology, biology and medical therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29905508" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prospective validation of a molecular prognostication panel for clival chordoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19801981" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : T (brachyury) gene duplication confers major susceptibility to familial chordoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32559743" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Clinical findings in families with chordoma with and without T gene duplications and in patients with sporadic chordoma reported to the Surveillance, Epidemiology, and End Results program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21266383" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical features distinguish childhood chordoma associated with tuberous sclerosis complex (TSC) from chordoma in the general paediatric population.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
